Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
作者信息
Penson David F
机构信息
Urologic Oncology,, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 1200, Nashville, TN, 37203-1738, USA,
出版信息
J Gen Intern Med. 2013 Nov;28(11):1494. doi: 10.1007/s11606-013-2513-2.
Abstract
摘要
相似文献
1
Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.关于沙希尼安等人的简要评论：接受雄激素剥夺治疗的前列腺癌男性的骨矿物质密度检测模式。
J Gen Intern Med. 2013 Nov;28(11):1494. doi: 10.1007/s11606-013-2513-2.
2
Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.男性前列腺癌去势治疗后骨密度检测模式。
J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.
3
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.在接受雄激素剥夺治疗且无明显骨转移的前列腺癌患者中，通过双能X线吸收法测量的骨矿物质密度、瘦体重和脂肪含量的变化。
J Urol. 2002 Jun;167(6):2361-7; discussion 2367.
4
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.前列腺癌男性患者的雄激素剥夺与骨丢失率增加有关。
Prostate Cancer Prostatic Dis. 2002;5(4):304-10. doi: 10.1038/sj.pcan.4500599.
5
Screening for osteoporosis in men receiving androgen deprivation therapy.接受雄激素剥夺治疗的男性骨质疏松症筛查。
JAMA. 2012 Jan 18;307(3):255-6. doi: 10.1001/jama.2011.2022.
6
Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial.唑来膦酸对接受雄激素剥夺治疗的男性的骨微结构和骨密度的影响不同：一项随机对照试验。
J Bone Miner Res. 2020 Oct;35(10):1871-1880. doi: 10.1002/jbmr.4106. Epub 2020 Jul 6.
7
Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.年龄、体重指数和血清前列腺特异性抗原与未接受雄激素剥夺治疗的前列腺癌男性的骨质流失相关。
Urology. 2004 Aug;64(2):335-40. doi: 10.1016/j.urology.2004.03.036.
8
The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.长期雄激素剥夺治疗后局部前列腺癌患者骨密度变化的临床意义。
J Urol. 2021 Jun;205(6):1648-1654. doi: 10.1097/JU.0000000000001646. Epub 2021 Feb 12.
9
Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.阿仑膦酸钠对接受雄激素剥夺治疗的前列腺癌男性骨密度的影响。
J Clin Densitom. 2006 Oct-Dec;9(4):431-7. doi: 10.1016/j.jocd.2006.07.005. Epub 2006 Sep 6.
10
The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.雄激素剥夺疗法对前列腺癌男性患者牙周疾病的影响。
J Urol. 2007 Mar;177(3):921-4. doi: 10.1016/j.juro.2006.10.067.
本文引用的文献
1
Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.男性前列腺癌去势治疗后骨密度检测模式。
J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.
2
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.一项 3 期、双盲、随机、平行分组、安慰剂对照研究，评估口服每周阿伦膦酸钠预防非转移性前列腺癌去势相关性骨丢失：用阿伦膦酸钠和亮丙瑞林进行癌症和骨质疏松症研究（CORAL）。
Eur Urol. 2013 May;63(5):927-35. doi: 10.1016/j.eururo.2012.09.007. Epub 2012 Sep 11.
3
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.地诺单抗用于接受雄激素剥夺治疗的前列腺癌男性患者。
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
4
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.唑来膦酸治疗激素难治性转移性前列腺癌患者的一项随机、安慰剂对照试验。
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
Zotero 插件